Sofosbuvir
- Generic Name
- Sofosbuvir
- Brand Names
- Epclusa, Harvoni, Sovaldi, Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FN3O9P
- CAS Number
- 1190307-88-0
- Unique Ingredient Identifier
- WJ6CA3ZU8B
- Background
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, ...
- Indication
Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 2, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- PharmEvo Pvt Ltd
- Target Recruit Count
- 573
- Registration Number
- NCT02804386
- Locations
- 🇵🇰
Ojha, Duhs, Karachi, Sindh, Pakistan
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
- Conditions
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT02781649
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Target Recruit Count
- 150
- Registration Number
- NCT02771405
- Locations
- 🇪🇬
Amr Maged, Cairo, Egypt
Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Instituto de Investigación Marqués de Valdecilla
- Target Recruit Count
- 64
- Registration Number
- NCT02768961
- Locations
- 🇪🇸
Penitentiary "El Dueso". Cantabria. Spain, Santoña, Cantabria, Spain
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02717949
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Cornell Medical Center, New York, New York, United States
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT02705534
- Locations
- 🇮🇷
Shariati Hospital, Tehran, Iran, Islamic Republic of
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 26
- Registration Number
- NCT02647632
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 506
- Registration Number
- NCT02640157
Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)
- Conditions
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02601573
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT02596880
- Locations
- 🇮🇷
Shariati Hospital, Tehran, Iran, Islamic Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.